U

Our purpose

To improve life during and beyond sedation

Sedana Medical is a pioneer medtech and pharmaceutical company dedicated to making inhaled sedation a standard therapy in intensive care.

Bringing inhaled sedation to intensive care

We are proud to introduce inhaled sedation to intensive care, a paradigm shift in the care of critically ill patients.

Through the results obtained in the pivotal study with Sedaconda (isoflurane) and Sedaconda ACD, we have laid the foundation for inhaled sedation in intensive care.

By this, we have also taken a major step closer to our vision – to make inhaled sedation a standard therapy in intensive care.

Learn more

Sedana Medical Clinical Development Program

We are proud to introduce inhaled sedation to intensive care, a paradigm shift in the care of critically ill patients.

Through the results obtained in the pivotal study with Sedaconda (isoflurane) and Sedaconda ACD, we have laid the foundation for inhaled sedation in intensive care.

By this, we have also taken a major step closer to our vision – to make inhaled sedation a standard therapy in intensive care.

Learn more

Sedaconda ACD

Sedaconda ACD (Anaesthetic Conserving Device) is a medical device enabling delivery of inhaled sedation to invasively ventilated patients.

Learn more

Using Sedaconda ACD

Improve your knowledge about our products with our Training Material and Frequently Asked Questions.

Learn more

Our Products

Explore our broad portfolio of products for the administration of inhaled sedation.

Learn more
acd

Sedaconda ACD-S

acd

Sedaconda ACD Starter Kit

Adapter

Adapters

Scavenging-Flurabsorb

Scavenging / Flurabsorb

Press Releases

2026

Sedana Medical announces FDA acceptance for review of its New Drug Application in the U.S.
2026-08-19 07:30
Sedana Medical AB (publ) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of the company's New Drug Application...
Sedana Medical AB’s Interim report January-June 2026
2026-07-17 07:00
Regulatory MAR
NDA submission and improved EBITDA Second quarter 2026 January-June 2026 CEO comments NDA submission and improved EBITDA We submitted our New Drug Application...
See More

Financial Calendar

See More